Feasibility and Cost of Robot-assisted Upper Limb Rehabilitation with Different Levels of Supervision

Launched by SWISS FEDERAL INSTITUTE OF TECHNOLOGY · Dec 4, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the use of a new robot-assisted device called ReHandyBot to help patients with upper limb impairments caused by conditions like stroke or traumatic brain injuries. The goal is to see if this device can be used safely and effectively with little to no supervision, allowing patients to get more therapy without needing extra resources like physical therapists. By increasing the amount of therapy, researchers hope to improve patients' abilities to perform daily activities and enhance their overall quality of life.

To participate in this trial, individuals must be between 18 and 90 years old and have an upper limb deficit that could benefit from robot therapy. Participants will use ReHandyBot in both clinical settings and at home, and the study will gather information on how well the device works and how much it costs compared to traditional therapy. This could represent an important step in making rehabilitation more accessible and effective for those who need it.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Informed Consent signed by the subject.
• • Female and male patients between 18 and 90 years old
• • Presence of an upper limb deficit derived from any disease or event that, according to the responsible clinicians, could be improved by therapy with ReHandyBot.
• Exclusion Criteria:
• • Pathologies that may interfere with the training with ReHandyBot.